REVOLUTION Medicines Inc (RVMD)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$210.02-0.40%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · RVMD
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Progress late-stage clinical trials and regulatory filings for daraxonrasib in pancreatic and lung cancers, including NDA submission and Expanded Access Program.
Stated as a priority in 2 of last 2 quarters. Management highlighted FDA acceptance of daraxonrasib NDA and launch of Expanded Access Program distributing drug to over 2,000 patients by 2026-Q2. Phase 3 trial RASolute 302 showed median overall survival improved from 6.7 to 13.2 months in 2026-Q1. The trajectory is delivering with regulatory progress and clinical advancement.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 0 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 28% of the time over the next year (vs 52% for the rest of the cohort, n=10029).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“FDA accepted daraxonrasib NDA; Expanded Access Program launched; ongoing Phase 3 studies in pancreatic and lung cancers.”
“Positive Phase 3 RASolute 302 results; NDA submission planned; Expanded Access Program initiated for daraxonrasib.”
Progress Phase 3 trials and combination studies of zoldonrasib and elironrasib in non-small cell lung cancer and pancreatic cancer.
Stated as a priority in 2 of last 2 quarters. Management reported ongoing Phase 3 trials and encouraging clinical data for zoldonrasib and elironrasib in NSCLC and pancreatic cancer. While no precise financial metrics are available, the clinical progress and trial initiations indicate active delivery on this priority.
“Presented encouraging data for zoldonrasib and elironrasib in NSCLC; ongoing Phase 3 trials in PDAC and NSCLC.”
“Advancing zoldonrasib and elironrasib in multiple Phase 3 studies in NSCLC and PDAC; clinical collaborations ongoing.”
Establish commercial infrastructure and prepare for potential U.S. launch and international regulatory approvals of daraxonrasib.
Stated as a priority in 2 of last 2 quarters. Management reported achieving U.S. launch readiness and expanding global commercialization infrastructure including leadership hires. While financial impact is not quantified, the company is delivering on building commercial capabilities ahead of potential product approvals.
“Achieved U.S. commercial launch readiness and accelerated global commercialization build out.”
“Expanded commercialization capabilities globally with new leadership appointments in JPAC and Europe.”
Control GAAP operating expenses in 2026 within the updated guidance range of $2.1 to $2.2 billion.
Stated as a priority in 2 of last 2 quarters. Management raised 2026 GAAP operating expense guidance from $1.7-$1.8B in Q1 to $2.1-$2.2B in Q2, reflecting higher stock-based compensation. Operating expenses increased from $445.2M in Q1 to $505.1M in Q2. The trajectory shows rising expenses consistent with updated guidance, indicating management is managing within the revised range.
“Updating full year 2026 GAAP operating expense guidance to $2.1 to $2.2 billion.”
“Previously guided full year 2026 GAAP operating expenses to $1.7 to $1.8 billion.”
Raise capital through public offerings of common stock and convertible senior notes to support operations and growth.
Stated as a priority in 2 of last 2 quarters. Management completed $1.725B common stock and $500M convertible notes offerings in April 2026, raising $2.225B gross proceeds. Cash and equivalents increased to $3.9B by 2026-Q2. The capital raises strengthened the balance sheet as planned, delivering on this priority.
“Completed concurrent upsized public offerings of $1.725B common stock and $500M convertible notes.”
“Strengthened financial position with financings totaling $2.2B in gross proceeds.”
Over the trailing year it converted 0.88x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, Fed net liquidity, long-term interest rates (low R² over the window).
14 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated volatile grew net income 53% of the time over the next year (vs 50% for the rest of the cohort, n=3986).
Not investment advice. As of 2026-09-04.